Healthcare-Associated Gram-Negative Infections – EpiCast Report, Emerging Trends, Growth and Future Forecast to 2026

366
0
SHARE

Albany, NY — (SBWIRE) — 09/08/2017 — New study report and forecast on “EpiCast Report: Healthcare-Associated Gram-Negative Infections – Epidemiology Forecast to 2026″

Summary

Healthcare-associated infections (HAIs) are a major threat to patient safety. HAIs occur in hospitalized patients, and are not present at the time of admission. The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infections caused by Gram-negative bacteria are of particular public health concern, since they are at the root of approximately 30-70% of HAIs across the globe.

GlobalData epidemiologists forecast that the suspected incident cases of CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an Annual Growth Rate (AGR) of 0.60% per year over the next 10 years, from 2,592,739 cases in 2016 to 2,747,836 in 2026. In the 7MM, the US will have the highest number of suspected incident cases, with 1,311,068 in 2016, while Japan will have the lowest number of suspected incident cases, with 84,847 in 2016.

Request To Get The Sample Copy Of This Report : https://www.marketresearchreports.biz/sample/sample/1319636

GlobalData epidemiologists forecast that the diagnosed incident cases of Gram-negative CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an AGR of 0.55% per year over the next 10 years, from 1,116,853 cases in 2016 to 1,178,754 cases in 2026. In the 7MM, the US will have the highest number of diagnosed incident cases, with 505,544 in 2016, while Japan will have the lowest number of diagnosed incident cases, with 41,245 in 2016.

GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from national nosocomial surveillance systems and peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the suspected incident cases of HAIs and diagnosed incident cases of Gram-negative HAIs. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for suspected and diagnosed incident cases of Gram-negative HAIs.

Browse Pharmaceutical Market Research Reports : https://www.marketresearchreports.biz/category/38

Scope

– The Healthcare-Associated Gram-Negative Infections EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of healthcare-associated Gram-negative infections in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the suspected incident cases of healthcare-associated infections (HAIs) and diagnosed incident cases of Gram-negative HAIs in acute care, in men and women combined, ages 18 years and older, segmented by select infection sites: catheter-associated urinary tract infection (CAUTI), central line-associated blood stream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infection site-specific diagnosed incident cases of Gram-negative HAIs are further segmented by causative agent (Acinetobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa).

– The Healthcare-Associated Gram-Negative Infections epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Send An Enquiry : https://www.marketresearchreports.biz/sample/enquiry/1319636

Reasons to buy

The Healthcare-Associated Gram-Negative Infections EpiCast report will allow you to –

– Develop business strategies by understanding the trends shaping and driving the global Gram-negative HAI market.

– Quantify patient populations in the global Gram-negative HAI market to improve product design, pricing, and launch plans.

– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gram-negative HAI therapeutics in each of the markets covered.

– Identify the percentage of suspected and diagnosed incident cases of Gram-negative HAIs by various clinical segmentations.

To order report Call Toll Free: 866-997-4948 or send an email on [email protected]

Powered by WPeMatico